Abstracts tagged "Biomarkers and systemic lupus erythematosus (SLE)"

Abstract Number: 685 • 2012 ACR/ARHP Annual Meeting
Using a Library of Synthetic Autoantigen Mimics to Discover Biomarkers of Systemic Lupus Erythematosus
Akshai Lakhanpal¹, Jiexia Quan², Sayed Zaman¹, Nancy J. Olsen³ and David R. Karp², ¹Rheumatic Diseases Divsion, UT Southwestern Medical Center, Dallas, TX, ²Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ³Medicine, Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: The natural history of systemic lupus erythematosus (SLE) is felt to evolve from a state of normal immunity to serologic autoimmunity and then…
Abstract Number: 615 • 2012 ACR/ARHP Annual Meeting
Baseline Laboratory Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials Are Predictive of Severe Flare At 52 Weeks
Michelle Petri¹, Ronald F. van Vollenhoven², Roger A. Levy³, Sandra V. Navarra⁴, Ricard Cervera⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Jill P. Buyon⁷, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Karolinska University Hospital, Stockholm, Sweden, ³Medicine, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Hospital Clinic, Barcelona, Spain, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Identification and validation of potential serologic biomarkers of clinically meaningful SLE flare are major unmet medical needs in clinical practice and trials. The purpose…
Abstract Number: 617 • 2012 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels Reflect Organ Damage in Systemic Lupus Erythematosus
Helena Enocsson¹, Jonas Wetterö², Thomas Skogh³ and Christopher Sjöwall⁴, ¹Deparment of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Deparment of clinical and experimental medicine, Linkoping University, Linkoping, Sweden
Background/Purpose: Disease activity assessment in systemic lupus erythematosus (SLE) remains a challenge due to lack of reliable biomarkers and disease heterogeneity. Ongoing tissue inflammation can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].